Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

NCT05090410 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis
JAK Inhibitor
IL-6 Inhibitor
Musculoskeletal Ultrasound
Biomarker

Interventions

DRUG: filgotinib 200mg/day
DRUG: subcutaneous tocilizumab 162mg/biweekly

Sponsor

Atsushi Kawakami

Collaborators

[object Object]